I still believe the best shot at income is a partnership, not an EUA which may or may not come in the foreseeable future.Both NASH and Tnbc , along with HIV are the future of the company....they are very attractive to large pharmas if the study data holds up .a partnership alone can bring in 100's of millions of dolars alone if not more, and the license to big pharma to sell the drug and share in the profits is big.
I do expect excellent topline results from Dr. Recknor on the NASH study which was due out about 5 weeks ago. I've been a bit outspoken on Covid critical since the cd12 data came out last Spring and have been hoping they shut it down to focus on the bigger picture or sell the license for that purpose to perhaps Pfizer who has a couple of treatments , one to prevent covid (vaccine) and another to treat early stage covid with their new pill. what they dont have is a drug for seriously ill/ critically ill covid patients and this drug could fill thier gap in their product line...